Initiator Pharma A/S (INIT.ST)
SEK 6.36
(1.92%)
SEK 6.36
(1.92%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -27.02 Thousand DKK | 99.94% |
| 2022 | -41.72 Thousand DKK | -81.0% |
| 2021 | -23.06 Million DKK | -119.52% |
| 2020 | -10.5 Thousand DKK | -13.54% |
| 2019 | -9252.00 DKK | 26.12% |
| 2018 | -12.52 Thousand DKK | -32.14% |
| 2017 | -9477.00 DKK | -983.09% |
| 2016 | -1312.50 DKK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -3.57 Million DKK | -100.0% |
| 2024 Q2 | -4.99 Million DKK | 0.0% |
| 2023 Q3 | -5.19 Million DKK | 41.56% |
| 2023 Q4 | 10.54 Thousand DKK | 100.2% |
| 2023 FY | - DKK | 99.94% |
| 2023 Q1 | -8.67 Million DKK | -33.97% |
| 2023 Q2 | -8.88 Million DKK | -2.36% |
| 2022 Q4 | -6.47 Million DKK | 3.17% |
| 2022 FY | - DKK | -81.0% |
| 2022 Q3 | -6.68 Million DKK | 50.45% |
| 2022 Q2 | -13.49 Million DKK | 10.45% |
| 2022 Q1 | -15.07 Million DKK | -107.07% |
| 2021 Q4 | -7.28 Million DKK | 19.61% |
| 2021 Q3 | -9.05 Million DKK | -83.36% |
| 2021 Q2 | -4.93 Million DKK | -176.54% |
| 2021 FY | - DKK | -119.52% |
| 2021 Q1 | -1.78 Million DKK | 13.43% |
| 2020 Q1 | -2.38 Million DKK | 3.99% |
| 2020 Q2 | -3.01 Million DKK | -26.35% |
| 2020 Q3 | -3.04 Million DKK | -1.23% |
| 2020 FY | - DKK | -13.54% |
| 2020 Q4 | -2.06 Million DKK | 32.32% |
| 2019 Q4 | -2.48 Million DKK | -27.48% |
| 2019 FY | - DKK | 26.12% |
| 2019 Q3 | -1.94 Million DKK | 42.43% |
| 2019 Q2 | -3.38 Million DKK | -134.7% |
| 2019 Q1 | -1.44 Million DKK | 42.04% |
| 2018 Q3 | -3.67 Million DKK | -12.38% |
| 2018 FY | - DKK | -32.14% |
| 2018 Q4 | -2.48 Million DKK | 32.39% |
| 2018 Q1 | -3.08 Million DKK | 19.58% |
| 2018 Q2 | -3.27 Million DKK | -5.92% |
| 2017 FY | - DKK | -983.09% |
| 2017 Q1 | -1.19 Million DKK | -68.74% |
| 2017 Q3 | -2.43 Million DKK | -21.64% |
| 2017 Q4 | -3.84 Million DKK | -57.81% |
| 2017 Q2 | -2 Million DKK | -67.73% |
| 2016 Q4 | -707 Thousand DKK | -331.1% |
| 2016 Q2 | -5000.00 DKK | 0.0% |
| 2016 Q3 | -164 Thousand DKK | -3180.0% |
| 2016 FY | - DKK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Lipum AB (publ) | -37.11 Million SEK | 99.927% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 99.989% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 1451.45% |
| BioArctic AB (publ) | 275.38 Million SEK | 100.01% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | 98.701% |
| Mendus AB (publ) | -97.84 Million SEK | 99.972% |
| Genovis AB (publ.) | 64.57 Million SEK | 100.042% |
| CombiGene AB (publ) | -35.33 Million SEK | 99.924% |
| Intervacc AB (publ) | -68.98 Million SEK | 99.961% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 99.799% |
| Active Biotech AB (publ) | -43.88 Million SEK | 99.938% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 100.086% |
| Ziccum AB (publ) | -20.34 Million SEK | 99.867% |
| Camurus AB (publ) | 562.54 Million SEK | 100.005% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 99.984% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 99.951% |
| Aptahem AB (publ) | -10 Million SEK | 99.73% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 99.991% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 99.984% |
| Kancera AB (publ) | -61.88 Million SEK | 99.956% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 100.234% |
| Fluicell AB (publ) | -25.91 Million SEK | 99.896% |
| Saniona AB (publ) | -69.69 Million SEK | 99.961% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | 99.777% |
| Biovica International AB (publ) | -119.5 Million SEK | 99.977% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 99.936% |
| AcouSort AB (publ) | -16.7 Million SEK | 99.838% |
| Xintela AB (publ) | -53.47 Million SEK | 99.949% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 99.842% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 99.99% |
| Abliva AB (publ) | -93.6 Million SEK | 99.971% |
| Corline Biomedical AB | -1.69 Million SEK | 98.402% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 99.899% |
| OncoZenge AB (publ) | 7.26 Million SEK | 100.372% |
| Amniotics AB (publ) | -27.14 Million SEK | 99.9% |
| 2cureX AB (publ) | -35.13 Million SEK | 99.923% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 99.992% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | 99.81% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 99.993% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 99.927% |
| I-Tech AB | 30.34 Million SEK | 100.089% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 99.996% |
| Cyxone AB (publ) | -20.41 Million SEK | 99.868% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 99.974% |
| Biosergen AB | 228 Thousand SEK | 111.855% |
| Cantargia AB (publ) | -284.31 Million SEK | 99.99% |
| NextCell Pharma AB | -40.98 Million SEK | 99.934% |
| Nanologica AB (publ) | -62.11 Million SEK | 99.956% |
| SynAct Pharma AB | -222.7 Million SEK | 99.988% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 99.938% |
| LIDDS AB (publ) | -39.67 Million SEK | 99.932% |
| BioInvent International AB (publ) | -312.7 Million SEK | 99.991% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | 99.764% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 108.736% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 164.356% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 99.975% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 99.988% |
| Pila Pharma AB (publ) | -8.81 Million SEK | 99.693% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 99.976% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 99.862% |
| Simris Alg AB (publ) | -22.36 Million SEK | 99.879% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 99.981% |